Communiqués Edesa Biotech, Inc.

Actions

EDSA

CA27966L3065

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
4,28 ^USD	0,00%		-2,28%	-6,35%

24/06	La BARDA sélectionne le médicament d'Edesa Biotech pour un essai de plate-forme financé par les États-Unis dans le cadre du SDRA général	CI
10/05	Edesa Biotech, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	12/04	AQ
Edesa Biotech to Participate in Barclays Global Healthcare Conference	08/03	AQ
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug	26/10/23	AQ
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate	29/09/23	AQ
Edesa Biotech to Participate in Swiss Biotech Day	21/04/23	AQ
Edesa Biotech - The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate	05/04/23	AQ
EDESA BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	27/03/23	AQ
EDESA BIOTECH, INC. : Regulation FD Disclosure (form 8-K)	13/03/23	AQ
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results	13/02/23	AQ
EDESA BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/02/23	AQ
EDESA BIOTECH, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	10/02/23	AQ
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug	18/01/23	AQ
Edesa Biotech Reports Fiscal Year 2022 Results	19/12/22	AQ
EDESA BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	16/12/22	AQ
EDESA BIOTECH, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	16/12/22	AQ
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference	05/12/22	AQ
EDESA BIOTECH, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	03/11/22	AQ
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study	03/10/22	AQ
Edesa Biotech : Reports Fiscal 3rd Quarter 2022 Results - Form 8-K	12/08/22	PU
EDESA BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	12/08/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Edesa Biotech, Inc.

Actions

EDSA

CA27966L3065

Communiqués

Filtres